Quegen Biotech is a company focusing on manufacturing beta-glucan for use in a range of healthcare products, from hangover cures to oncology treatments. In this interview, Dr Jong Dae Lee explains the benefits of beta glucan, and how he managed to overcome the challenges in its extraction to make it a commercially viable venture. Dr Lee also discusses his plans to expand the scope of Quegen Biotech’s operations into pharmaceuticals.
We reached a breakeven point in 2016, which is always a key milestone for any biotech company. Now we have the ambition of achieving revenues of USD 78 million by 2022, and plan to launch an IPO on the KOSDAQ next year
